Top Stories
CT-155 improved motivation and pleasure-related negative symptoms when used alongside antipsychotic medication, with researchers reporting a small-to-moderate treatment effect.
The Neuralink competitor has raised $430 million in total as it works to commercialise its wireless brain-computer interface (BCI) system.
Despite the incident occurring in June, the government wasn't notified until a few weeks ago, when an email was sent to a public mailbox.
The deal follows a $787-million financing for Earendil, backed by Sanofi and Pfizer.
Amgen, Lilly and Merck & Co. are among the investors backing the biotech's agentic data platform for rapid protein design.
Conference News
Mayo Clinic researchers found the model reliably separated at-risk from low-risk individuals using routine health records, in findings to be presented at the American College of Surgeons Clinical Cong...
SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys...
Reports and ProceedingsEuropean Society for Emergency Medicine (EUSEM)Paris, France: Researchers in The Netherlands have found that about 30% of presentations to emergency departments of patients with...
Beyond treatment intent, the complete clinical workflow will include tools for the physician, physicist, dosimetrist, therapist and nurse. It builds on collaboration with the University of Michigan an...
Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregio...
